Spravato (Esketamine) Nasal Spray

Learn More about Spravato

Spravato is the first prescription nasal spray, taken with an oral antidepressant.

It works similarly to ketamine and is best for:

Adults with treatment-resistant depression

Adults who were struggling with major depressive disorder and had not responded adequately to at least two different antidepressants in the current episode

Depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions

Excellent results:

  • Typical antidepressant medications are slow-acting and can take several weeks to feel any significant reduction in symptoms.
  • Spravato Esketamine immediately targets brain cells, offering relief of depressive symptoms in as little as 24 hours.

SPRAVATO® (esketamine) CIII nasal spray is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. It is a first-of-its kind medicine approved by the FDA in two major depressive disorder (MDD) subpopulations with high unmet need.

SPRAVATO® is approved in the United States, in conjunction with an oral antidepressant to treat adults with treatment-resistant depression (TRD) and to treat depressive symptoms in adults with MDD with acute suicidal ideation or behavior.​

SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:

  • Adults with treatment-resistant depression (TRD)
  • Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic).

We are now Risk Evaluation and Mitigation Strategy (REMS)-certified to provide SPRAVATO® (esketamine) CIII, a nasal spray approved for use, in conjunction with an oral antidepressant, to treat depressive symptoms in adults with MDD with acute suicidal ideation or behavior.

Our medical staff are trained to prescribe, dispense and administer SPRAVATO®, and we have established processes and procedures in accordance with the REMS. A healthcare provider will provide direct supervision as the patient self-administers SPRAVATO® and will monitor every patient after every dose for at least two hours for resolution of sedation and dissociation and changes in vital signs. SPRAVATO® must never be dispensed directly to a patient for home use.

Additionally, all patients require transportation from our clinic following the observation period, as they should not drive or operate machinery until the day after a treatment session, following a restful sleep.

The use of Spravato with medications has been shown to produce significant reduction of depressive symptoms as quickly as 24 hours.

If you continue to experience significant depressive symptoms despite having tried two or more antidepressants and/or with therapy, talk to our psychiatrist about Spravato.

Most Common Side Effects:​

  • Dissociation
  • Dizziness
  • Lack of energy
  • Nausea
  • Vomiting
  • Feeling Sleepy
  • Feeling drunk
  • Spinning sensation
  • Feeling anxious
  • Numbness
  • Feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

Do not take if you have a history of:

  • Blood vessel disease (aneurysm)
  • You have an abnormal connection between your blood vessels (arteriovenous malformation)
  • You have a history of bleeding in the brain
  • You are allergic to esketamine or a similar medicine called ketamine used for anesthesia or any of the other ingredients in SPRAVATO®